Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 1/2017

Open Access 01-12-2017 | Letter to the editor

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world

Authors: Giorgio Ciprandi, Valentina Natoli, Paola Puccinelli, Cristoforo Incorvaia, Italian Cometa Study Group

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2017

Login to get access

Abstract

As standard drug treatment of allergic rhinitis (AR) is not completely satisfactory, allergen immunotherapy (AIT) represents the only current treatment with the potential to modify the natural history. House dust mite (HDM) allergy is very common. The aim of the current experience was to describe the clinical profile of HDM-allergic patients with AR who received AIT in a real world model, such as allergy clinics. Globally, 239 patients (126 adults and 113 children; 107 females and 132 males; mean age 21 years, age range 6–56 years) were evaluated. AIT was prescribed in 59 patients (24.7%), 44 adults (35%) and 15 children (13.3%). The current findings deriving from this real world multicentre study are consistent with previous investigations on HDM-AIT and define some clinical characteristics of the eligible candidate to this treatment. In fact, severity of ocular-nasal symptoms and over-use of symptomatic medications may typify the ideal candidate to HDM-AIT and SLIT was the preferred choice.
Literature
1.
Bernstein DI, Schwartz G, Bernstein JA. Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin North Am. 2016;36(2):261–78.CrossRefPubMed
2.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8–160.CrossRefPubMed
3.
Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339–49.CrossRefPubMed
4.
Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132(6):1322–36.CrossRefPubMed
5.
Ciprandi G, Incorvaia C, Masieri S, Buttafava S, Frati F. The best allergen immunotherapy choice for mite allergic patients. Expert Rev Clin Immunol. 2016;12(6):603–4.CrossRefPubMed
6.
Karaman S, Can D, Erdem SB, Nacaroglu HT, Karkiner CS, Gunay I. Is there any parameter helpful for predicting a suitable candidate for mite immunotherapy? Iran J Allergy Asthma Immunol. 2016;15(2):105–11.PubMed
7.
Platts-Mills TA, Hayden ML, Chapman MD, Wilkins SR. Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. J Allergy Clin Immunol. 1987;79:781–91.CrossRefPubMed
8.
Gelardi M, Peroni DG, Incorvaia C, Quaranta N, De Luca C, Barberi S, et al. Seasonal changes in nasal cytology in mite-allergic patients. J Inflamm Res. 2014;7:39–44.PubMedPubMedCentral
9.
Leatherman B, Skoner DP, Hadley JA, Walstein N, Blaiss MS, Dykewicz MS, Craig T, Smith N, Allen-Ramey F. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy. Int Forum Allergy Rhinol. 2014;4(10):779–88.CrossRefPubMed
10.
Lynch SV, Wood RA, Boushey H, Bacharier LB, Bloomberg GR, Kattan M, et al. Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. J Allergy Clin Immunol. 2014;134(3):593–601.CrossRefPubMedPubMedCentral
Metadata
Title
Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
Authors
Giorgio Ciprandi
Valentina Natoli
Paola Puccinelli
Cristoforo Incorvaia
Italian Cometa Study Group
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2017
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-017-0185-x

Other articles of this Issue 1/2017

Allergy, Asthma & Clinical Immunology 1/2017 Go to the issue

Research

Regulation of Th2 responses by different cell types expressing the interleukin-31 receptor

Research

Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012–2015

Research

Oral food challenge outcomes in a pediatric tertiary care center

Research

Prevalence of allergen sensitization in 1000 adults in Saskatchewan

Research

Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children

Research

Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study